BANGKOK — Renowned international speakers and healthcare professionals from 17 countries sought innovative solutions and collaborative strategies to address pressing global challenges in respiratory diseases and advance respiratory health worldwide.

The third annual RespiVerse Meeting was hosted by global biopharmaceutical company GSK on December 13 and 14 in Bangkok, Thailand.

The event featured prominent international speakers and participants from regions including Southeast Asia, Latin America, Central America, and others.

It integrated science, technology, and talent to identify the main clinical challenges in the respiratory area to develop scientific content that enhances the knowledge and professional practices of pulmonologists in Southeast Asia, the Middle East, Africa, and Latin America.

The expert panel focused on four respiratory pathologies: moderate asthma, severe asthma, chronic obstructive pulmonary disease (COPD), and respiratory syncytial virus (RSV).

Dr. Gur Levy, Respiratory Medical Expert at GSK, said the company has been pioneering efforts for decades to develop new therapeutic alternatives that set the standard for next-generation treatments and redefine the future of respiratory medicines for hundreds of millions of people with respiratory diseases.

By establishing a collaboration involving top-level specialist physicians and highly qualified experts from around the world, it has developed a world-class programme to achieve excellence in clinical practices and optimise new respiratory treatment outcomes for millions of patients.

“We research and develop a portfolio of vaccines, targeted biological products, and inhaled medicines at the forefront of the respiratory sector, aiming to improve outcomes and enhance the lives of people suffering from all types of asthma, COPD, and RSV,” he said.

GSK is leveraging the latest scientific and technological advances to address the underlying dysfunction of these diseases and prevent their progression.

Dr. Arnas Berzanskis, VP & Regional Medical Affairs Head - Vaccines at GSK, said GSK is dedicated to advancing innovative solutions to protect vulnerable populations, particularly older adults, especially those with underlying medical conditions such as asthma, COPD, diabetes, and heart disease, from the significant health risks posed by RSV and other acute respiratory infections.

“By prioritising prevention, we aim to ease the burden on the healthcare system and promote healthier communities worldwide, especially in the context of an aging global society,” he said.

Other renowned experts discussed the primary causes and consequences of respiratory diseases affecting populations worldwide and highlighted the challenges that still need to be overcome. — VNS